Bio-Rad Laboratories (BIO-B) Non-Current Deffered Revenue (2015 - 2016)
Bio-Rad Laboratories (BIO-B) reported Non-Current Deffered Revenue of $4.4 million for Q3 2016, up 17.55% on a QoQ basis from $3.7 million in Q4 2015.
Bio-Rad Laboratories (BIO-B) has 2 years of Non-Current Deffered Revenue data on file, last reported at $4.4 million in Q3 2016.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $4.4 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $4.4 million (changed N/A YoY) and the FY2015 annual result came in at $3.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue improved to $4.4 million in Q3 2016 per BIO-B's latest filing, from $3.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $4.4 million in Q3 2016 and bottomed at $3.7 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 512.79 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Bio-Rad Laboratories | - | - | 309.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 4.40 Mn |
| Dec 31, 2015 | 3.74 Mn |